iifl-logo

Biocon Ltd EGM

330.05
(-0.17%)
Jun 6, 2025|12:00:00 AM

Biocon CORPORATE ACTIONS

07/06/2024calendar-icon
07/06/2025calendar-icon

No Record Found

Biocon: Related News

Biocon gets six-month extension on insulin supply pact
22 May 2025|12:42 PM

In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months.

Read More
Biocon shares zoom ~2% after drug launch in Japan
21 May 2025|11:41 AM

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

Read More
Biocon Q4 Net Profit Soars 154% YoY to ₹344.5 Crore
11 May 2025|08:59 AM

The operating performance was also good as EBITDA increased 17.7% to ₹1,078.2 crore in March quarter compared with ₹915.9 crore in Q4 FY24.

Read More
Biocon Biologics Secures Multiple Market Access for Yesintek
5 May 2025|03:48 PM

Yesintek has been added to Express Scripts' National Preferred Formulary (NPF), effective March 21, 2025.

Read More
Biocon to Raise ₹4,500 Crore; Approves Capital Expansion Plan
24 Apr 2025|09:50 PM

The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.

Read More
Top Stocks for Today - 24th April 2025
24 Apr 2025|06:20 AM

Here are some of the stocks that may see significant price movement today: LTIMindtree, Dalmia Bharat, Bajaj Housing, etc.

Read More
Biocon unit expands oncology portfolio after USFDA approval
11 Apr 2025|09:00 AM

Jobevne is a vascular endothelial growth factor (VEGF) impediment that sticks with VEGF and restrain the interaction with its receptors.

Read More
Biocon Pharma Gains USFDA Approval for Norepinephrine and Key Therapies
24 Mar 2025|11:51 PM

The first approval is for the 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths of Lenalidomide Capsules.

Read More
Biocon Biologics inks pact with Civica to expand access in US
7 Mar 2025|08:53 AM

Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.

Read More
Biocon Secures USFDA Approval for Dasatinib
5 Mar 2025|01:40 PM

The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults who have shown resistance or intolerance to prior therapy.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.